Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing

Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29.


Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at for the use of abacavir based on HLA-B genotype.

Publication types

  • Practice Guideline
  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Dideoxynucleosides / administration & dosage*
  • Genotype*
  • HLA-B Antigens / genetics*
  • Humans
  • Pharmacogenetics / methods
  • Pharmacogenetics / standards*
  • Reverse Transcriptase Inhibitors / administration & dosage*


  • Dideoxynucleosides
  • HLA-B Antigens
  • Reverse Transcriptase Inhibitors
  • abacavir